In a meta-analysis reported in JAMA Oncology, Magnan et al found that intermittent androgen-deprivation therapy was noninferior to continuous androgen-deprivation therapy with respect to overall survival in patients with prostate cancer. Study Details A literature review identified 22 articles...
A study that tracked tens of thousands of middle-aged and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may cut their chances of developing a lethal type of prostate cancer by up to 68%. While most prostate cancers are clinically indolent, a...
Scientists from Lawrence Livermore National Laboratory (LLNL), in collaboration with researchers from University of California Merced and Davis, have found that a secreted protein predominantly expressed in bone inhibits prostate cancer metastasis to bone. Their research was published recently by...
Men with prostate cancer who are undergoing radiation therapy can benefit from yoga, researchers at the Perelman School of Medicine at the University of Pennsylvania reported at the Society for Integrative Oncology’s 12th International Conference. The new, first-of-its-kind study, led...
In a phase II trial reported in The New England Journal of Medicine, Mateo et al found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated metastatic castration-resistant prostate cancer with tumors exhibiting defects in DNA repair genes....
University of California, Los Angeles (UCLA) researchers have described costs across the entire care process for low-risk prostate cancer—from the time a patient checks in for his first appointment to his post-treatment follow-up testing—using time-driven activity-based costing. For the ...
Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
For men with prostate cancer who have had a prostatectomy and salvage radiation therapy, analyzing their tumor genome provides clues as to whether their cancer will metastasize, thereby enabling clinicians to better personalize treatment options, according to research presented by Den et al...
Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...
A long-term follow-up of RTOG 9202 indicated that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen-deprivation therapy after radiation therapy plus short-term androgen-deprivation therapy improved disease-free survival by 60%, compared to patients...
In a UK phase III noninferiority trial reported in the Journal of the National Cancer Institute, Hoskin et al found similar effects of single-dose ibandronate and single-dose radiotherapy on localized metastatic bone pain in patients with prostate cancer. Study Details In the open-label trial,...
A study to examine racial disparities in end-of-life care among black and white patients dying of prostate cancer found that “significant racial disparities in end-of-life care" do exist. “Although diagnostic and therapeutic interventions are less frequent in black patients with...
A prospective study of guideline-based, postoperative, image-guided intensity-modulated radiation therapy in patients with prostate cancer found low toxicity profiles and favorable patient-reported quality of life following treatment, with researchers concluding that toxicity and health-related...
As reported in the Journal of Clinical Oncology by Tosoian et al, a prospective active surveillance program resulted in good intermediate/longer-term outcomes in men with favorable-risk prostate cancer. Study Details The program included 1,298 men with very-low-risk or low-risk disease enrolled...
Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy alone vs radiotherapy and androgen-deprivation therapy, according to a study described in a research letter in JAMA. In the letter, ...
In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...
Duke University researchers found that packaging the widely used cancer drug paclitaxel into nanoparticles more than doubled the drug’s effectiveness in destroying tumors in preclinical models. Their findings were published by Bhattacharyya et al in Nature Communications. Paclitaxel has been ...
In a study reported in Journal of Clinical Oncology, Yamoah et al identified a biomarker signature that may predict aggressive disease in African American men with prostate cancer. Study Details In the study, distribution of mRNA expression levels of 20 biomarkers associated with prostate cancer...
A large-scale genetic study of the links between telomere length and risk for five common cancers found that long telomeres are associated with an increased risk of lung adenocarcinoma. No significant associations between telomere length and other cancer types or subtypes were observed. The study,...
Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....
In a retrospective study reported in JAMA Oncology, Kalbasi et al found that dose-escalated external-beam radiation therapy was associated with improved overall survival among men with intermediate- and high-risk, but not low-risk, nonmetastatic prostate cancer. Study Details The study involved...
After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at the University of California, San...
UCLA Jonsson Cancer Center scientists have identified a new mechanism that delivers a key substance that fuels the growth of pancreatic and prostate cancer cells, a finding that offers new hope in the fight against two of the deadliest forms of the disease. Their findings were published by...
Researchers at Thomas Jefferson University reported finding a single molecule that appears to be the central regulator driving metastasis in prostate cancer. The study, published by Goodwin et al in Cancer Cell, offers a target for the development of a drug that could prevent metastasis in prostate ...
A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the United States declined 28% in the year following the draft recommendation from the U.S. Preventive Services Task Force (USPSTF) against routine prostate-specific antigen (PSA)...
Statin use has been associated with improved outcome in prostate cancer. In a study reported in JAMA Oncology, Harshman et al found that statin use at the time of initiation of androgen-deprivation therapy was associated with prolonged time to progression during androgen-deprivation therapy in men...
In a study reported in the Journal of Clinical Oncology, Brundage et al found that the addition of radiotherapy to androgen-deprivation therapy in patients with locally advanced prostate cancer in the NCIC CTG PR3/MRC PR07 trial had a transient negative impact on health-related quality of life over ...
In a small clinical trial, scientists at Johns Hopkins Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant. The...
In an analysis reported in the Journal of the National Cancer Institute, Lin et al found that the addition of radiotherapy to androgen-deprivation therapy was associated with a significant improvement in overall survival in patients with clinically node-positive prostate cancer. Study Details The ...
In a study reported in JAMA Oncology, Beltran et al found that whole-exome sequencing of metastatic and treatment-resistant cancers revealed biologically informative alterations in the majority of cases. Although treatment recommendations could be made in the majority of cases, treatment was guided ...
A study led by the University at Buffalo (UB) and Roswell Park Cancer Institute (RPCI) has identified beliefs and personality traits associated with higher levels of distress in patients with newly diagnosed prostate cancer. The findings support the value of emotional and informational support for...
In a French phase III trial (GETUG 12) reported in The Lancet Oncology, Fizazi et al found that the addition of docetaxel and estramustine (Emcyt) to androgen-deprivation therapy (ADT) improved relapse-free survival among patients with high-risk localized prostate cancer. Study Details In the...
A recent analysis of a large observational study has revealed that men with a history of asthma are less likely than those without it to develop lethal prostate cancer, researchers at Johns Hopkins reported. These findings were published by Platz et al in the International Journal of Cancer....
“For the first time, improvement in overall survival was observed with tolerable adjuvant chemotherapy for localized, high-risk prostate cancer,” Howard Sandler, MD, Professor of Radiation Oncology at Cedars-Sinai Medical Center in Los Angeles, announced at a press briefing at the...
A large study evaluating the relationship of dietary patterns with prostate cancer–specific and all-cause mortality among men diagnosed with nonmetastatic prostate cancer has found that the men who ate a Western-style diet of foods rich in processed meats, red meats, and high-fat dairy...
In men who experience biochemical disease recurrence after local therapy for prostate cancer, docetaxel, bevacizumab (Avastin), and androgen-deprivation therapy may be beneficial, according to a study by McKay et al in Cancer. Further evaluation of this combination treatment is warranted to...
In an analysis of participants in the SELECT prevention trial reported in JAMA Oncology, Barrington et al found that obesity in African American men was associated with a greater risk of prostate cancer than in white men. African American men have the highest prostate cancer incidence and mortality ...
Active surveillance has become a viable option for many men with low-risk prostate cancer who choose not to undergo active treatment such as surgery or radiotherapy. Four studies evaluating effectiveness, trends, and other considerations for active surveillance in managing prostate cancer were...
Prostate cancer is one of the most common cancers in American men, yet controversy over the utilization and frequency of prostate-specific antigen (PSA) screening methods remains, due to the overdiagnosis and overtreatment of men with low-grade, less-aggressive forms of the disease. At the 110th...
A new urine-based test improved prostate cancer detection—including detecting more aggressive forms of prostate cancer—compared to traditional models based on prostate-specific antigen (PSA) levels. The results were published by Tomlins et al in European Urology. The test, developed at ...
To provide guidance on high-value cancer care screening strategies, the American College of Physicians (ACP) recently reviewed clinical guidelines issued by various medical organizations for screening strategies in five common cancers for asymptomatic, average-risk adults. The five cancers focused...
Cognitive impairment can occur in cancer patients who are treated with a variety of therapies, including radiation therapy, hormone therapy, and chemotherapy. This side effect, when occurring with chemotherapy, is commonly referred to as “chemobrain.” Signs of cognitive impairment...
The UK-led STAMPEDE trial found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone-naive). Men who received docetaxel plus standard therapy lived on...
The PREVAIL trial showed that enzalutamide (Xtandi) improved overall survival and progression-free survival vs placebo in asymptomatic/minimally symptomatic chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In analyses reported in The Lancet Oncology, Loriot et al...
Despite strong evidence and guidelines supporting its use, postsurgical radiation therapy for prostate cancer patients at risk of tumor recurrence is declining in the United States. The study, published by Sineshaw et al in European Urology, finds fewer than 10% of patients at risk of tumor...
Results presented on April 24 at The International Liver Congress 2015 (Abstract O058) in Vienna, Austria, show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV...
In a randomized phase II trial (SWOG S0925) reported in the Journal of Clinical Oncology, Yu et al found that the addition of cixutumumab to androgen-deprivation therapy did not significantly increase the rate of undetectable prostate-specific antigen (PSA) in patients with newly diagnosed...
A combination of two molecularly targeted drugs, olaparib (Lynparza) and the investigational agent AZD5363, was safe and yielded responses in patients with a variety of cancer types, including breast, ovarian, and prostate cancers, regardless of BRCA1/2-mutation status, according to data from the...
Men with metastatic, castration-resistant prostate cancer who had mutations in genes linked to repair of damaged DNA were significantly more likely to respond to treatment with olaparib (Lynparza) compared with patients who had the disease without these mutations. These findings from the first...